# A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study

> **NCT03710252** · PHASE4 · COMPLETED · sponsor: **American Research Corporation** · enrollment: 100 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin

## Key facts

- **NCT ID:** NCT03710252
- **Lead sponsor:** American Research Corporation
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2018-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03710252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03710252, "A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03710252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*